The Indian pharmaceutical industry is a success story providing employment for mi llions and ensuring that essential drugs

at affordable prices are available to t he vast population of this sub-continent. Richard Gerster http://www.pharmaceutical-drug-manufacturers.com/articles/top-10-pharmaceuticalcompanies-in-india.html The Indian Pharmaceutical Industry today is in the front rank of India s science-b ased industries with wide ranging capabilities in the complex field of drug manu facture and technology. It ranks very high in the third world, in terms of techn ology, quality and range of medicines manufactured. From simple headache pills t o sophisticated antibiotics and complex cardiac compounds, almost every type of medicine is now made indigenously. Playing a key role in promoting and sustaining development in the vital field of medicines, Indian Pharma Industry boasts of quality producers and many units ap proved by regulatory authorities in USA and UK. International companies associat ed with this sector have stimulated, assisted and spearheaded this dynamic devel opment in the past 53 years and helped to put India on the pharmaceutical map of the world. Growth Scenario in 2010 India's pharmaceutical industry is now the third largest in the world in terms o f volume. Its rank is 14th in terms of value. Between September 2008 and Septemb er 2009, the total turnover of India's pharmaceuticals industry was US$ 21.04 bi llion. The domestic market was worth US$ 12.26 billion. This was reported by the Department of Pharmaceuticals, Ministry of Chemicals and Fertilizers. As per a report by IMS Health India, the Indian pharmaceutical market reached US$ 10.04 b illion in size in July 2010. A highly organized sector, the Indian Pharma Indust ry is estimated to be worth $ 4.5 billion, growing at about 8 to 9 percent annua lly. Know more out this in our article on Indian Pharmaceutical Industry- Future Trends Also check out Pharmaceutical Market Trends 2010 Leading Pharmaceutical Companies In the domestic market, Cipla retained its leadership position with 5.27 per cen t share. Ranbaxy followed next. The highest growth was for Mankind Pharma (37.2% ). Other leading companies in the Indian pharma market in 2010 are: Sun Pharma (25.7%) Abbott (25%) Zydus Cadila (24.1%) Alkem Laboratories (23.3%) Pfizer (23.6 %) GSK India (19%) Piramal Healthcare (18.6 %) Lupin (18.8 %) For details check out List of Top 10 Pharmaceutical Companies in India Future Prospects The Indian pharmaceuticals market is expected to reach US$ 55 billion in 2020 fr om US$ 12.6 billion in 2009. This was stated in a report title "India Pharma 202 0: Propelling access and acceptance, realising true potential" by McKinsey & Com pany. In the same report, it was also mentioned that in an aggressive growth sce nario, the pharma market has the further potential to reach US$ 70 billion by 20 20 Due to increase in the population of high income group, there is every likelihoo d that they will open a potential US$ 8 billion market for multinational compani es selling costly drugs by 2015. This was estimated in a report by Ernst & Young . The domestic pharma market is estimated to touch US$ 20 billion by 2015. The h ealthcare market in India to reach US$ 31.59 billion by 2020. The sale of all ty pes of pharmaceutical drugs and medicines in the country stands at US$ 9.61 bill ion, which is expected to reach around US$ 19.22 billion by 2012. Thus India wou

ld really become a lucrative destination for clinical trials for global giants. There was another report by RNCOS titled "Booming Pharma Sector in India" in whi ch it was projectedt that the pharmaceutical formulations industry is expected t o prosper in the same manner as the pharmaceutical industry. The domestic formul ations market will grow at an annual rate of around 17% in 2010-11, owing to inc reasing middle class population and rapid urbanisation. Read More in Future Pros pects of Indian Pharma Industry. Characteristics of Indian Pharmaceutical Industry The Indian Pharmaceutical sector is highly fragmented with more than 20,000 regi stered units. It has expanded drastically in the last two decades. The leading 2 50 pharmaceutical companies control 70% of the market with market leader holding nearly 7% of the market share. It is an extremely fragmented market with severe price competition and government price control. The pharmaceutical industry in India meets around 70% of the country's demand fo r bulk drugs, drug intermediates, pharmaceutical formulations, chemicals, tablet s, capsules, orals and injectibles. There are about 250 large units and about 80 00 Small Scale Units, which form the core of the pharmaceutical industry in Indi a (including 5 Central Public Sector Units). These units produce the complete ra nge of pharmaceutical formulations, i.e., medicines ready for consumption by pat ients and about 350 bulk drugs, i.e., chemicals having therapeutic value and use d for production of pharmaceutical formulations. Following the de-licensing of the pharmaceutical industry, industrial licensing for most of the drugs and pharmaceutical products has been done away with. Manuf acturers are free to produce any drug duly approved by the Drug Control Authorit y. Technologically strong and totally self-reliant, the pharmaceutical industry in India has low costs of production, low R&D costs, innovative scientific manpo wer, strength of national laboratories and an increasing balance of trade. The P harmaceutical Industry, with its rich scientific talents and research capabiliti es, supported by Intellectual Property Protection regime is well set to take on the international market. Why India? Competent workforce: India has a pool of personnel with high managerial and tech nical competence as also skilled workforce. It has an educated work force and En glish is commonly used. Professional services are easily available. Cost-effective chemical synthesis: Its track record of development, particularly in the area of improved cost-beneficial chemical synthesis for various drug mol ecules is excellent. It provides a wide variety of bulk drugs and exports sophis ticated bulk drugs. Legal & Financial Framework: India has a 53 year old democracyand hence has a so lid legal framework and strong financial markets. There is already an establishe d international industry and business community. Information & Technology: It has a good network of world-class educational insti tutions and established strengths in Information Technology. Globalisation: The country is committed to a free market economy and globalizati on. Above all, it has a 70 million middle class market, which is continuously gr owing. Consolidation: For the first time in many years, the international pharmaceutica l industry is finding great opportunities in India. The process of consolidation , which has become a generalized phenomenon in the world pharmaceutical industry , has started taking place in India.

Steps to strengthen the Industry Indian companies need to attain the right product-mix for sustained future growt h. Core competencies will play an important role in determining the future of ma ny Indian pharmaceutical companies in the post product-patent regime after 2005. Indian companies, in an effort to consolidate their position, will have to incr easingly look at merger and acquisition options of either companies or products. This would help them to offset loss of new product options, improve their R&D e fforts and improve distribution to penetrate markets. Research and development has always taken the back seat amongst Indian pharmaceu tical companies. In order to stay competitive in the future, Indian companies wi ll have to refocus and invest heavily in R&D. The Indian pharmaceutical industry also needs to take advantage of the recent ad vances in biotechnology and information technology. The future of the industry w ill be determined by how well it markets its products to several regions and dis tributes risks, its forward and backward integration capabilities, its R&D, its consolidation through mergers and acquisitions, co-marketing and licensing agree ments. List of Top 10 Pharmaceutical Companies in India: In the list of top pharmaceutical companies in India it is not the Indian compan ies but also the MNCs that are becoming the part of the race. Indian pharmaceuti cal market in 2008 was $7,743m and if compared to year 2007 it was 4% more than that. It is expected that Indian pharmaceutical market will grow more than the g lobal pharmaceutical market and will become $15,490 million in 2014. Today India n pharmaceutical industry is the second most fastest growing industry displaying the revenue of Rs 25,196.48 crore and growth of 27.32 percent. Top pharmaceutic al companies in India are also acquiring the small companies worldwide to furthe r expand the market. Pharmaceutical drugs injections, tablets, capsules, syrups are the products of pharma companies in India along with many more. Looking back into history reveals that it was in 1930 when the first pharmaceuti cal company in India came into existence in Kolkatta. It is called the "Bengal C hemicals and Pharmaceutical Works". This Indian company is still there and today it is the part of five drug manufacturing companies that are owned by the gover nment. Till the period of 60 years the pharmaceutical industry in India was over shadowed by the foreign drug manufacturing companies but with the Patent Act in 1970, the whole scenario of pharmaceutical companies in India had changed since then. With this the Indian market was more open to Indian pharmaceutical compani es than the MNCs. So with this pharmaceutical companies in India started to grow in number At present there is a cut throat competition among top pharmaceutical companies in India with the native as well as MNCs. But there are certain issue s that are concerning the growth of pharma companies in India. These are: Mandatory licensing and failure of new paten system. Regular power cuts and inadequate infrastructure. Restricted funding. Regulatory hindrances that lead to the delays in the launch of new drug or pharm a product. Too many small as well as big pharmaceutical companies and excessive competition . Top 10 Pharmaceutical Companies in India Ranbaxy With a 2007 turnover of Rs 4,198.96 crore (Rs 41.989 billion) by sales, Ranbaxy is the largest pharmaceutical company in India. Dr Reddy's Laboratories

With the turnover of Rs 4,162.25 crore (Rs 41.622 billion), Dr Reddy's Laborator ies is the second largest pharmaceutical company in India. Cipla With the revenue of Rs 3,763.72 crore (Rs 37.637 billion) Cipla is the third lar gest pharmaceutical company in India. Sun Pharma Industries Sun Pharma Industries is the fourth largest pharma company in India with the tot al revenue of Rs 2,463.59 crore (Rs 24.635 billion) and led by Dilip Sanghvi. Lupin Labs Lupin Labs has the total revenue of Rs 2,215.52 crore (Rs 22.155 billion Aurobindo Pharma Sales revenues stood at Rs 2,080.19 crore (Rs 20.801 billion) makes it the sixth largest pharmaceutical company in India. GlaxoSmithKline Pharma (GSK) GSK is the seventh largest pharma company with the total sales revenue of Rs 1,7 73.41 crore (Rs 17.734 billion) Cadila Healthcare Eight largest company has the total sale revenue at Rs 1,613.00 crore (Rs 16.13 billion) Aventis Pharma Aventis Pharma has the revenue of Rs 983.80 crore (Rs 9.838 billion) and the nin th largest pharmaceutical company in India. Ipca Laboratories Revenue of Rs 980.44 crore (Rs 9.804 billion) makes Ipca India's 10th largest ph arma firm by sales.

http://en.wikipedia.org/wiki/Pharmaceutical_industry_in_India

The Indian pharmaceutical industry is the world's second-largest by volume and i s likely to lead the manufacturing sector of India.[1] The earliest pharmaceutical companies in india are Bengal Chemicals, Pharmaceuti cal Works, IDPL etc which still exist today as one of 5 government-owned drug ma nufacturers, appeared in Calcutta in 1903. For the next 60 years, most of the dr ugs in India were imported by multinationals either in fully formulated or bulk form. The government started to encourage the growth of drug manufacturing by Indian c ompanies in the early 1960s, and with the Patents Act in 1970. However, economic liberalization in 90s by the former Prime Moinister Narasimha Rao Pamulaparti ( PV Rao) and the then Finance Minister and current Prime Minister Manmohan Singh enabled the industry to become what it is today. This patent act removed composi tion patents from food and drugs, and though it kept process patents, these were shortened to a period of five to seven years. The lack of patent protection mad e the Indian market undesirable to the multinational companies that had dominate d the market, and while they streamed out, Indian companies started to take thei r places. They carved a niche in both the Indian and world markets with their expertise in reverse-engineering new processes for manufacturing drugs at low costs. Althoug h some of the larger companies have taken baby steps towards drug innovation, th e industry as a whole has been following this business model until the present. Recent academic research on the Indian pharma industry argues that multinational corporations' investments in this Indian industry may have hurt independent inn

ovation as most major Indian companies now do contracted work. India's biopharmaceutical industry clocked a 17 percent growth with revenues of Rs.137 billion ($3 billion) in the 2009-10 financial year over the previous fisc al. Bio-pharma was the biggest contributor generating 60 percent of the industry 's growth at Rs.8,829 crore, followed by bio-services at Rs.2,639 crore and bioagri at Rs.1,936 crore.[2] Pharmaceutical Statistics: pharmaceutical industry today The number of purely Indian pharma companies is fairly low. Indian pharma indust ry is mainly operated as well as controlled by dominant foreign companies having subsidiaries in India due to availability of cheap labour in India at lowest co st. In 2002, over 20,000 registered drug manufacturers in India sold $9 billion worth of formulations and bulk drugs. 85% of these formulations were sold in Ind ia while over 60% of the bulk drugs were exported, mostly to the United States a nd Russia[25]. Most of the players in the market are small-to-medium enterprises ; 250 of the largest companies control 70% of the Indian market [1]. Thanks to t he 1970 Patent Act, multinationals represent only 35% of the market, down from 7 0% thirty years ago[20]. Most pharma companies operating in India, even the multinationals, employ Indian s almost exclusively from the lowest ranks to high level management. Mirroring t he social structure, firms are very hierarchical. Homegrown pharmaceuticals, lik e many other businesses in India, are often a mix of public and private enterpri se. Although many of these companies are publicly owned, leadership passes from father to son and the founding family holds a majority share. In terms of the global market, India currently holds a modest 1-2% share, but it has been growing at approximately 10% per year[27]. India gained its foothold o n the global scene with its innovatively engineered generic drugs and active pha rmaceutical ingredients (API), and it is now seeking to become a major player in outsourced clinical research as well as contract manufacturing and research. Th ere are 74 U.S. FDA-approved manufacturing facilities in India, more than in any other country outside the U.S, and in 2005, almost 20% of all Abbreviated New D rug Applications (ANDA) to the FDA are expected to be filed by Indian companies[ 21,27]. Growth in other fields notwithstanding, generics are still a large part of the picture. London research company Global Insight estimates that India s shar e of the global generics market will have risen from 4% to 33% by 2007[27].

Biotechnology Statistics: Patents: As it expands its core business, the industry is being forced to adapt its busin ess model to recent changes in the operating environment. The first and most sig nificant change was the January 1, 2005 enactment of an amendment to India s paten t law that reinstated product patents for the first time since 1972. The legisla tion took effect on the deadline set by the WTO s Trade-Related Aspects of Intelle ctual Property Rights (TRIPS) agreement, which mandated patent protection on bot h products and processes for a period of 20 years. Under this new law, India wil l be forced to recognize not only new patents but also any patents filed after J anuary 1, 1995.[3] Indian companies achieved their status in the domestic market by breaking these product patents, and it is estimated that within the next few years, they will lose $650 million of the local generics market to patent-holde rs[42].

In the domestic market, this new patent legislation has resulted in fairly clear segmentation. The multinationals narrowed their focus onto high-end patients wh o make up only 12% of the market, taking advantage of their newly bestowed paten t protection. Meanwhile, Indian firms have chosen to take their existing product portfolios and target semi-urban and rural populations[45]. [edit] Product development Indian companies are also starting to adapt their product development processes to the new environment. For years, firms have made their ways into the global ma rket by researching generic competitors to patented drugs and following up with litigation to challenge the patent. This approach remains untouched by the new p atent regime and looks to increase in the future. However, those that can afford it have set their sights on an even higher goal: new molecule discovery. Althou gh the initial investment is huge, companies are lured by the promise of hefty p rofit margins and the recognition as a legitimate competitor in the global indus try. Local firms have slowly been investing more money into their R&D programs o r have formed alliances to tap into these opportunities. [edit] Small and medium enterprises As promising as the future is for a whole, the outlook for small and medium ente rprises (SME) is not as bright. The excise structure changed so that companies n ow have to pay a 16% tax on the maximum retail price (MRP) of their products, as opposed to on the ex-factory price. Consequently, larger companies are cutting back on outsourcing and what business is left is shifting to companies with faci lities in the four tax-free states - Himachal Pradesh, Jammu & Kashmir, Uttaranc hal and Jharkhand.[12]Consequently a large number of pharmaceutical manufacturer s shifted their plant to these states, as it became almost impossible to continu e operating in non tax free zones. But in a matter of a couple of years the exci se duty was revised on two occasions, first it was reduced to 8% and then to 4%. As a result the benefits of shifting to a tax free zone was negated. This resul ted in, factories in the tax free zones, to start up third party manufacturing. Under this these factories produced goods under the brand names of other parties on job work basis. As SMEs wrestled with the tax structure, they were also scrambling to meet the J uly 1 deadline for compliance with the revised Schedule M Good Manufacturing Pra ctices (GMP). While this should be beneficial to consumers and the industry at l arge, SMEs have been finding it difficult to find the funds to upgrade their man ufacturing plants, resulting in the closure of many facilities. Others invested the money to bring their facilities to compliance, but these operations were loc ated in non-tax-free states, making it difficult to compete in the wake of the n ew excise tax. [edit] Challenges All of these changes are ultimately good for the Indian pharmaceutical industry, which suffered in the past from inadequate regulation and large quantities of s purious drugs. They force the industry to reach a level necessary for global com petitiveness. However, they have also exposed some of the inadequacies in the in dustry today. Its main weakness is an underdeveloped new molecule discovery prog ram. Even after the increased investment, market leaders such as Ranbaxy and Dr. Reddy s Laboratories spent only 5-10% of their revenues on R&D, lagging behind We stern pharmaceuticals like Pfizer, whose research budget last year was greater t han the combined revenues of the entire Indian pharmaceutical industry[13, 37]. This disparity is too great to be explained by cost differentials, and it comes when advances in genomics have made research equipment more expensive than ever. The drug discovery process is further hindered by a dearth of qualified molecul

ar biologists. Due to the disconnect between curriculum and industry, pharmas in India also lack the academic collaboration that is crucial to drug development in the West[13]. [edit] R&D Both the Indian central and state governments have recognized R&D as an importan t driver in the growth of their pharma businesses and conferred tax deductions f or expenses related to research and development. They have granted other concess ions as well, such as reduced interest rates for export financing and a cut in t he number of drugs under price control. Government support is not the only thing in Indian pharma s favor, though; companies also have access to a highly develope d IT industry that can partner with them in new molecule discovery in r&d. [edit] Labor force India s greatest strengths lie in its people. India also boasts of well-educated, English-speaking labor force that is the base of its competitive advantage. Alth ough molecular biologists are in short supply, there are a number of talented ch emists who are equally as important in the discovery process. In addition, there has been a reverse brain drain effect in which scientists are returning from ab road to accept positions at lower salaries at Indian companies. Once there, thes e foreign-trained scientists can transfer the benefits of their knowledge and ex perience to all of those who work with them[13,25]. India s wealth of people exten ds benefits to another part of the drug commercialization process as well. With one of the largest and most genetically diverse populations in any single countr y, India can recruit for clinical trials more quickly and perform them more chea ply than countries in the West[47]. Indian firms have just recently started to l everage. Biotechnology [edit] Relationship between pharmaceuticals and biotechnology Unlike in other countries, the difference between biotechnology and pharmaceutic als remains fairly defined in India. Bio-tech there still plays the role of phar ma s little sister, but many outsiders have high expectations for the future. Indi a accounted for 2% of the $41 billion global biotech market and in 2003 was rank ed 3rd in the Asia-Pacific region and 11th in the world in number of biotechs.[4 5] In 2004-5, the Indian biotech industry saw its revenues grow 37% to $1.1 bill ion.[2,9] The Indian biotech market is dominated by biopharmaceuticals; 75% of 2 004-5 revenues came from biopharmaceuticals, which saw 30% growth last year. Of the revenues from biopharmaceuticals, vaccines led the way, comprising 47% of sa les[46]. Biologics and large-molecule drugs tend to be more expensive than small -molecule drugs, and India hopes to sweep the market in biogenerics and contract manufacturing as drugs go off patent and Indian companies upgrade their manufac turing capabilities. Most companies in the biotech sector are extremely small, with only two firms br eaking 100 million dollars in revenues. At last count there were 265 firms regis tered in India, over 75% of which were incorporated in the last five years.[2,47 ] The newness of the companies explains the industry s high consolidation in both physical and financial terms. Almost 50% of all biotechs are in or around Bangal ore, and the top ten companies capture 47% of the market. The top five companies were homegrown; Indian firms account for 62% of the biopharma sector and 52% of the industry as a whole.[4,46] The Association of Biotechnology-Led Enterprises (ABLE) is aiming to grow the industry to $5 billion in revenues generated by 1 million employees by 2009, and data from the Confederation of Indian Industry (C II) seem to suggest that it is possible.[7,47]

[edit] Comparison with the U.S. The Indian biotech sector parallels that of the U.S. in many ways. Both are fill ed with small start-ups while the majority of the market is controlled by a few powerful companies. Both are dependent upon government grants and venture capita lists for funding because neither will be commercially viable for years. Pharmac eutical companies in both countries have recognized the potential effect that bi otechnology could have on their pipelines and have responded by either investing in existing start-ups or venturing into the field themselves.[36] In both India and the U.S., as well as in much of the globe, biotech is seen as a hot field w ith a lot of growth potential. [edit] Relationship with IT Many analysts have observed that the hype around the biotech sector mirrors that of the IT sector. Biotech colleges have been popping up around the country eage r to service the pools of students that want to take advantage of a growing indu stry.[7] The International Finance Commission, the private investment arm of the World Bank, called India the centerpiece of IFC s global biotech strategy. Of the $ 110 million invested in 14 biotech projects investment globally, the IFC has giv en $43 million to 4 projects in India.[29] According to Dr. Manju Sharma, former director of the Department of Biotechnology, the biotech industry could become the single largest sector for employment of skilled human resource in the years t o come. [5] British Prime Minister Tony Blair was similarly impressed, citing the success of India s biotech industry as the reason for his own country s own biotech opportunities.[22] Malaysia is also looking to India as an example for growing i ts own biotech industry.[41] [edit] Government support The Indian government has been very supportive. It established the Department of Biotechnology in 1986 under the Ministry of Science and Technology.[47] Since t hen, there have been a number of dispensations offered by both the central gover nment and various states to encourage the growth of the industry. India s science minister launched a program that provides tax incentives and grants for biotech start-ups and firms seeking to expand and establishes the Biotechnology Parks So ciety of India to support ten biotech parks by 2010. Previously limited to roden ts, animal testing was expanded to include large animals as part of the minister s initiative.[10] States have started to vie with one another for biotech busines s, and they are offering such goodies as exemption from VAT and other fees, fina ncial assistance with patents and subsidies on everything ranging from investmen t to land to utilities[19]. [edit] Foreign investment The government has also taken steps to encourage foreign investment in its biote ch sector. An initiative passed earlier this year allowed 100% foreign direct in vestment without compulsory licensing from the government1.[6] In April, a deleg ation headed by the Kapil Sibal, the minister of science and technology and ocea n development, visited five cities in the U.S. to encourage investment in India, with special emphasis on biotech.[32] Just two months later, Sibal returned to the U.S. to unveil India s biotech growth strategy at the BIO2005 conference in Ph iladelphia.[9] 100%of fdi is allowed in india. [edit] Challenges The biotech sector faces some major challenges in its quest for growth. Chief am ong them is a lack of funding, particularly for firms that are just starting out . The most likely sources of funds are government grants and venture capital, wh

ich is a relatively young industry in India. Government grants are difficult to secure, and due to the expensive and uncertain nature of biotech research, ventu re capitalists are reluctant to invest in firms that have not yet developed a co mmercially viable product.[26] As previously mentioned, India hopes to solve its funding problem by attracting overseas investors and partners. Before these pot ential saviors will invest significant sums in the industry, however, there need s to be better scientific and financial accountability. India is slowly working towards these goals, but it will be a while before they are up to the standards of Western investors. India s biotech firms share another problem with their pharmaceutical cousins: a l ack of qualified employees. Biotech has the additional disadvantage of competing against IT for ambitious, science-minded students but not being able to guarant ee the same compensation. An aspiring researcher in India needs 7 10 years of educ ation covering a range of specialties in order to qualify to work in biotech. Ev en if a student does choose to go on the biotech path, the ineffectual curriculu m at many universities makes it doubtful as to whether he will be qualified to w ork in the field once finished. One estimate shows that 10% of upper-echelon bio tech recruits have come from foreign countries. While this is not a problem, per se, it drives up cost in a country whose competitive advantage is based on chea p, high-quality labor. Far from ending with scientists, there is also a shortage of people with a knowledge of biotechnology in related fields: doctors, lawyers , programmers, marketing personnel and others.[7,15,17] While little has been done about the latter half of the employee crunch, the gov ernment has addressed the problem of educated but unqualified candidates in its Draft National Biotech Development Strategy. This plan included a proposal to cr eate a National Task Force that would work with the biotech industry to revise t he curriculum for undergraduate and graduate study in life sciences and biotechn ology. The government s strategy also stated intentions to increase the number of PhD Fellowships awarded by the Department of Biotechnology to 200 per year. Thes e human resources will be further leveraged with a Bio-Edu-Grid that will knit tog ether the resources of the academic and scientific industrial communities, much as they are in the U.S.[5] [edit] Major players [edit] Glenmark Glenmark is a emerging leader of Indian Pharmaceutical market in sales as well i n Research. Soon new chemical entities will hit the market. [edit] Ranbaxy Laboratories Ranbaxy is the leader in the Indian pharmaceutical market, taking in $1.174 bill ion in revenues for a net profit of $160 million in 2004. It was the first India n pharmaceutical to have a proprietary drug (extended-release ciprofloxacin, mar keted by Bayer) approved by the U.S. FDA, and the U.S. market accounts for 36% o f its sales. 78% of Ranbaxy s sales are from overseas markets; its offices in 44 c ountries manage manufacturing in 7 countries and distribution in over 100. IMS Health estimated that Ranbaxy is among the top 100 pharmaceuticals in the wo rld and that it is the 15th fastest growing company. By 2012, Ranbaxy hopes to b e one of the top 5 generics producers in the world, and it consolidated its posi tion with the purchase of French firm RGP Aventis in 2003. Ranbaxy also has high er aspirations, however, to build a proprietary prescription business in the adva nced markets. To this end, it keeps a dedicated research facility in Gurgaon staf fed with over 1100 scientists. They currently have two molecules in Phase II tri als and 3-5 in pre-clinical testing. It spent $75 million in R&D in 2004, a 43% increase over its 2003 expenditure.

Arun Puri is the chairman and CEO Brian Tempest is the only non-Indian on the se nior management team.38,39 [edit] Dr. Reddy's Laboratories Founded in 1984 with $160,000, Dr. Reddy s was the first Asia-Pacific pharmaceutic al outside of Japan and the sixth Indian company to be listed on the New York St ock Exchange. It earned $446 million in fiscal year 2005, deriving 66% of this i ncome from the foreign market. In order to strengthen its global position, Dr. R eddy acquired UK-based BMS Laboratories and subsidiary Meridian Healthcare. Anji Reddy is the chairman of Dr.Reddy's. Although 58% of Dr. Reddy s revenues come from generic drugs, the company was comm itted to WTO-compliance long before the 2005 bill took effect, and most of these products were already off patent. Dr. Reddy has long been a research-oriented f irm, preceding many of its peers in setting up a New Drug Development Research ( NDDR) in 1993 and out-licensing its first compound just four years later. Dr. Re ddy s has since outlicensed two more molecules and currently has three others in c linical trials. Although Dr. Reddy s is publicly traded, the Reddy family (including founder/chair man K. Anji Reddy, son-in-law/CEO GV Prasad and son/COO Satish Reddy) holds a he fty 26% share in the company.11,44 [edit] Nicholas Piramal The company led by Asish Mishra grossing $350 million per year, Nicholas Piramal started its existence with the 1988 acquisition of Nicholas Laboratories and gr ew through a series of mergers, acquisitions and alliances. The company has form ed a name for itself in the field of custom manufacturing. It cites its 1700-per son global sales force as another core strength; with its acquisition of Rhodia s inhalation anaesthetics business, Nicholas Piramal gained a sales and marketing network spanning 90 countries34. Nicholas Piramal is well-poised for the challenge of surviving in the aftermath of product patent protection. The company has respected intellectual property ri ghts since its inception and refused to "support generic companies seeking first -to-file or early-to-market strategies." Instead, it decided to make its own int ellectual property and opened a research facility last November in Mumbai with h opes of launching its first drug in 2010 at a cost of $100,000.24,33 [edit] Cipla Founded in 1935, Cipla is one of the oldest drug manufacturers in India. It is l ed by Dr. Yusuf K. Hamied, Chairman and Managing Director. Cipla burst into the international consciousness in 2000 with Triomune, an AIDS treatment costing bet ween $300 and $800 per year that combined three antiretroviral drugs patented by three different companies in most other countries, where the cocktail sold for as much as $16,000 per year. Long before this news, Cipla had been building a st rong global presence, and it now distributes its 800-odd products in over 140 co untries. Privately held Cipla holds a prominent spot in its home country as well ; it is the leader in domestic sales, having just unseated GlaxoSmithKline for t he first time in 28 years. Revenue in 2004 totaled $552 million (using Rs 43.472 = $1) about 75% of which was derived in India. Dr. Kiran Mazumdar-Shaw is the Chairman and Managing Director of BiocoIrish chem icals company seeking to break into the Indian market, Biocon is now the leading biotech in India, bringing in Rs 646.36 crore (almost $150 million) in revenue for fiscal year 2004. It initially made its money by producing enzymes, but Bioc

on recently decided to become a research-oriented company with the goal of bring ing a proprietary new drug to market. The company went public in March 2004, and "its shares were oversubscribed by 33 times on opening day." Eight months later it launched Insugen, a bio-insulin th at is its first branded product. Biocon also has two wholly owned subsidiaries, Syngene and Clinigene, that perform custom research and clinical trials.3,14,31 [edit] Serum Institute of India Main article: Serum Institute of India The Serum Institute of India can make the enviable claim that 2 out of every 3 c hildren in the world are immunized with one of their vaccines. It is the world s l argest producer of measles and DTP vaccines, and its portfolio includes other va ccines, antisera, plasma products and anticancer compounds. The Serum Institute earned Rs 565 crore ($130 million) in revenue in fiscal year 2005, selling mainl y to UN agencies and to the Indian government. The Serum Institute is part of th e Poonawalla Group, whose holdings include a horse stud farm and manufacturers o f industrial equipment and components. Dr. Cyrus Poonawalla is the Chairman of t he company.[4] [edit] Others Other important domestic companies Glenmark Generics Ltd. Mr. Glenn Saldana, MD Lupin Ltd :Dr. Desh Bandhu Gupta, Chairman Zee laboratories Ltd. :Mr. Rajiv Mukul, Chairman and Managing Director Sun Pharmaceuticals :Dilip S. Sanghvi, Chairman and Managing Director Torrent Pharmaceuticals :Sudir Mehta, Chairman Wockhardt :Habil F. Khorakiwala, Chairman Cadila Healthcare :Pankaj R. Patel, Chairman and Managing Director Hetero Drugs :Dr. B. Partha Saradhi Reddy, Chairman and Managing Director Nectar Lifesciences[5] :Mr. Sanjiv Goyal, Chairman Macleods Pharma[6] :Dr. Rajendra Agarwal, Managing Director Intas Biopharmaceuticals :Dr. Urmish Chudgar, Managing Director Bharat Serums[7] :Mr. Bharat V. Daftary, Chairman and Managing Director Orchid Pharmaceuticals :Mr. K. Raghavendra Rao, Chairman & Managing Director Zenbiz Life science Panacea Biotec[8] :Mr. Soshil Kumar Jain, Chairman AMN Pharmaceuticals[9] :Amndip, Chairman and Managing Director Ajanta Pharma[10] :Yogesh Agrawal, Managing Director Green Apple Lifesciences Limited[11] :Mitesh Mehta, Chairman

Reliance Life Sciences Pvt Ltd[12] : Mr. K.V. V. Subramaniam, President and CEO

http://business.mapsofindia.com/india-gdp/industries/pharmaceutical.html The Role of Pharmaceutical Industry in India GDP is immense. For the past few ye ars the Indian Pharmaceutical Industry is performing very well. The varied functions such as contract research and manufacturing, clinical resea rch, research and development pertaining to vaccines are the strengths of the Ph arma Industry in India. Multinational pharmaceutical corporations outsource thes e activities and help the growth of the sector. The Indian Pharmaceutical Indust ry has a bright future. Role of Pharmaceutical Industry in India GDP-Facts The Pharmaceutical Industry in India is one of the largest in the world It ranks 4th in the world, pertaining to the volume of sales The estimated worth of the Indian Pharmaceutical Industry is US$ 6 billion The growth rate of the industry is 13% per year Almost most 70% of the domestic demand for bulk drugs is catered by the Indian P harma Industry The Pharma Industry in India produces around 20% to 24% of the global generic dr ugs The Indian Pharmaceutical Industry is one of the biggest producers of the active pharmaceutical ingredients (API) in the international arena The Indian Pharma sector leads the science-based industries in the country The pharmaceutical sector has the capacity and technology pertaining to complex drug manufacturing Around 40% of the total pharmaceutical produce is exported 55% of the total exports constitute of formulations and the other 45% comprises of bulk drugs The Indian Pharma Industry includes small scaled, medium scaled, large scaled pl ayers, which totals nearly 300 different companies There are several other small units operating in the domestic sector Pharmaceutical Industry in India-Growth As per the present growth rate, the Indian Pharma Industry is expected to be a U S$ 20 billion industry by the year 2015 The Indian Pharmaceutical sector is also expected to be among the top ten Pharma based markets in the world in the next ten years The national Pharma market would experience the rise in the sales of the patent drugs The sales of the Indian Pharma Industry would worth US$ 43 billion within the ne xt decade With the increase in the medical infrastructure, the health services would be tr ansformed and it would help the growth of the Pharma industry further With the large concentration of multi national pharmaceutical companies in India , it becomes easier to attract foreign direct investments The Pharma industry in India is one of the major foreign direct investments enco uraging sectors Role of Pharmaceutical Industry in India GDP-CRAMS The Indian Pharmaceutical Industry is one of fastest emerging international cent er for contract research and manufacturing services or CRAMS The main factors for the growth of the CRAMS is due to the international standar d quality and low cost The estimated value of the CRAMS market in 2006 was US$ 895 million Indian already has the biggest number of US Food and Drug Administration (USFDA) standardized manufacturing units outside the territory of United States

Around 50 more new manufacturing units are to be set up in accordance to the USF DA and UK Medicines and Healthcare Regulatory Agency (MHRA) standards With all these development India is posed to become the biggest producer of drug s in the world Some of the major domestic players in this sector are Paras Pharma, Bal Pharma, Unijules Life Sciences, Flamingo Pharma, Venus Remedies, Surya Organics and Chem icals, Centaur Pharma, Kemwell, Coral Labs The contract manufacturing market in India pertaining to the multinational compa nies is expected to worth US$ 900 million by the year 2010 Role of Pharmaceutical Industry in India GD-India Advantage India has the advantage of the cost, as the cost of labor, the cost of inventory is much lower than other places The multinational companies, investing in research and development in India may save upto 30% to 50% of the expenses incurred The cost of hiring a research chemist in the US is five times higher than its In dian counterpart The manufacturing cost of pharmaceutical products in India is nearly half of the cost incurred in US The cost of performing clinical trials in India is one tenth of the cost incurre d in US The cost of performing research in India is one eighth of the cost incurred in U S

http://www.pharmaceutical-drug-manufacturers.com/articles/pharmaceutical-markettrends-2010.html The global pharmaceutical market research has been done by many companies and al most all of the market reports indicate a significant growth of pharma market in 2010-2011. The forecasting indicates pharmaceutical market growth of about 4 6% in 2010-2011. The established markets, including the US, UK, and Japan, toget her account for 30% of the global demand for pharmaceutical excipients. Pharmaceutical Industry Trends- Global Scenario If present industry overview is taken into consideration then the global pharmac eutical market in 2010 is projected to grow 4 - 6% exceeding $825 billion. The g lobal pharmaceutical market sales is expected to grow at a 4 - 7% compound annua l growth rate (CAGR) through 2013. This industry growth is driven by stronger ne ar-term growth in the US market and is based on the global macroeconomy, the cha nging combination of innovative and mature products apart from the rising influe nce of healthcare access and funding on market demand. Global pharmaceutical mar ket value is expected to expand to $975+ billion by 2013. Different regions of t he world will influence the pharmaceutical industry trends in different ways. Asia Pacific Pharmaceutical Market The pharma market world over will experience significant shifts. Asia-Pacific re gion will emerge as the fastest growing pharmaceutical market over the recent pa st. The reason for this positive shift can be attributed to the low costs and fa vorable regulatory environment. This region has experienced important developmen ts regarding contract manufacturing, especially in generics and APIs. Increased R&D activities in the region has helped Asia-Pacific pharmaceutical industry to achieve an estimated market size of around US$ 187 Billion in 2009. Here, the ph armaceutical industry is expected to grow at a CAGR of around 12.6% during 20102012. It can, in fact, become the global API production hub in next few years. pharmaceutical sales are growing at a fast rate in India, China, Malaysia, South Korea and Indonesia due to the rising disposable income, several health insuran

ce schemes (that ensures the sales of branded drugs), and intense competition am ong top pharmaceutical companies in the region (that has boosted the availabilit y of low cost drugs). China s pharmaceutical market will continue to grow at a 20+ % annually, and will contribute 21% of overall global growth through 2013. Indi a - 3rd Largest Producer of Pharmaceuticals Across the World- is already a US$ 8 .2 Billion pharmaceutical market. The Indian pharmaceutical industry is further expected to grow by 10% in the year 2010. Middle East Pharmaceutical Market The Middle East combined with the African Pharmaceutical market is projected to grow at a CAGR of around 11% during 2010-2012. The development of infrastructure and rapidly changing regulations in this region are being seen as the cause of its growth. Also there is a high prevalence of diseases and huge population base that increases the overall pharmaceutical sales in this part of the world. Pres ently South Africa, Saudi Arabia and Israel dominate the region's pharmaceutical industry due to their better infrastructure and regulatory environment. However , The Middle East pharma market depends on imported pharmaceutical drugs and the rapeutics. The governments of countries in this region are taking measures to ra ise their domestic production through heavy investments in the pharmaceutical in dustry. How far they are successful in the attempt of becoming considerable phar ma production center remains to be seen. Pharmaceutical Drugs Trends Anti-Diabetic Drugs and those for cardiovascular diseases are expected to see th e fastest growth in 2011. Cardiovascular patients will increase to 251 million i n 2010, with the greatest rate of growth forecast for the US market. This is due to the changes in demographics and lifestyle that will boost the cardiovascular sales. However, the growth rates will be limited by continued patent expiries f or major products and due to the lack of of novel therapies. The anti-hypertensi ves drugs will dominate the global cardiovascular market with a market share of nearly 50%.

http://www.coolavenues.com/know/gm/vipin_4.php3 http://www.india-reports.com/RNCOS/pharma.aspx